MedTrace Logo

Phase I Hypofractionated Stereotactic Boost (Radiotherapy) for Non-Small Cell Lung Cancer

NCT02252796 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2018-05-30

No results posted yet for this study

Summary

This study will help researchers test the safety of hypofractionated dose of radiotherapy (HySBst) at different dose levels before or after chemo-radiation for Non Small Cell Lung Cancer.

Conditions

Interventions

RADIATION

Hypofractionated Stereotactic Boost

An ablative dose of radiation is delivered to the primary tumor target over a week through Stereotactic Ablative Radiotherapy.

DRUG

Carboplatin

Given during chemo-radiation phase and optional consolidative phase.

DRUG

Paclitaxel

Given during chemo-radiation phase and optional consolidative phase.

RADIATION

Image-guided IMRT

Given during chemo-radiation phase

Sponsors & Collaborators

  • West Virginia University

    lead OTHER

Principal Investigators

  • Malcolm Mattes, MD · West Virginia University - Mary Babb Randolph Cancer Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-07-31
Primary Completion
2017-09-30
Completion
2017-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02252796 on ClinicalTrials.gov